Effect of Abatacept on Vaccine Response
Author Information
Author(s): Tay Lee, Leon Francisco, Vratsanos George, Raymond Ralph, Corbo Michael
Primary Institution: Bristol-Myers Squibb
Hypothesis
What is the effect of a single dose of abatacept on the antibody response to tetanus toxoid and pneumococcal vaccines in healthy subjects?
Conclusion
Abatacept blunts the immune response to vaccines but does not significantly inhibit the ability to develop a clinically significant immune response.
Supporting Evidence
- Subjects receiving vaccines 2 weeks after abatacept had lower antibody responses compared to control.
- Over 60% of subjects across all groups generated at least a twofold increase in antibody response to tetanus.
- More than 70% of subjects responded to at least three pneumococcal serotypes.
Takeaway
This study looked at how a drug called abatacept affects how well vaccines work in healthy people. It found that while the drug makes vaccines less effective, people can still build a good immune response.
Methodology
This was a randomized, open-label, parallel-group, controlled study with 80 healthy volunteers receiving different timing of vaccinations relative to abatacept administration.
Potential Biases
Potential bias in randomization and variability in baseline antibody levels among groups.
Limitations
The study was conducted in healthy subjects, which may not fully represent responses in patients with rheumatoid arthritis.
Participant Demographics
Healthy adults aged 18-65, with a mean age of 34-36 years, including both males and females.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website